No­var­tis' TV ad for breast can­cer drug Kisqali draws un­ti­tled let­ter from FDA

The FDA sent No­var­tis a rep­ri­mand last week claim­ing “false or mis­lead­ing” in­for­ma­tion in a TV com­mer­cial for metasta­t­ic breast can­cer drug Kisqali. The TV ad with a “Long Live” tagline, which is no longer run­ning, be­gan in 2022 and last aired in Sep­tem­ber 2023, No­var­tis said.

The com­mer­cial was de­scribed as con­cern­ing be­cause it could lead MBC pa­tients “to be­lieve that Kisqali has been shown to be more ef­fec­tive in treat­ing their con­di­tion and symp­toms (e.g., with re­spect to over­all sur­vival and qual­i­ty of life) than was ac­tu­al­ly demon­strat­ed,” ac­cord­ing to the un­ti­tled let­ter from the FDA’s ad­ver­tis­ing watch­dog, the Of­fice of Pre­scrip­tion Drug Pro­mo­tion (OPDP).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER